Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

559 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study.
Klein NP, Abu-Elyazeed R, Povey M, Macias Parra M, Diez-Domingo J, Ahonen A, Korhonen T, Tinoco JC, Weiner L, Marshall GS, Silas PE, Sarpong KO, Ramsey KP, Fling JA, Speicher D, Campos M, Munjal I, Peltier C, Vesikari T, Baccarini C, Caplanusi A, Gillard P, Carryn S, Henry O. Klein NP, et al. Among authors: korhonen t. J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):194-201. doi: 10.1093/jpids/piz010. J Pediatric Infect Dis Soc. 2020. PMID: 30849175 Free PMC article. Clinical Trial.
Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months.
Vesikari T, Karvonen A, Lindblad N, Korhonen T, Lommel P, Willems P, Dieussaert I, Schuerman L. Vesikari T, et al. Among authors: korhonen t. Pediatr Infect Dis J. 2010 Jun;29(6):e47-56. doi: 10.1097/INF.0b013e3181dffabf. Pediatr Infect Dis J. 2010. PMID: 20508478 Clinical Trial.
Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when administered as catch-up vaccination to children 7 months to 5 years of age.
Vesikari T, Karvonen A, Korhonen T, Karppa T, Sadeharju K, Fanic A, Dieussaert I, Schuerman L. Vesikari T, et al. Among authors: korhonen t. Pediatr Infect Dis J. 2011 Aug;30(8):e130-41. doi: 10.1097/INF.0b013e31821d1790. Pediatr Infect Dis J. 2011. PMID: 21540760 Clinical Trial.
Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials.
Vesikari T, Richardus JH, Berglund J, Korhonen T, Flodmark CE, Lindstrand A, Silfverdal SA, Bambure V, Caplanusi A, Dieussaert I, Roy-Ghanta S, Vaughn DW. Vesikari T, et al. Among authors: korhonen t. Pediatr Infect Dis J. 2015 Jul;34(7):774-82. doi: 10.1097/INF.0000000000000709. Pediatr Infect Dis J. 2015. PMID: 26069949 Clinical Trial.
Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
Vesikari T, Rivera L, Korhonen T, Ahonen A, Cheuvart B, Hezareh M, Janssens W, Mesaros N. Vesikari T, et al. Among authors: korhonen t. Hum Vaccin Immunother. 2017 Jul 3;13(7):1505-1515. doi: 10.1080/21645515.2017.1294294. Epub 2017 Mar 24. Hum Vaccin Immunother. 2017. PMID: 28340322 Free PMC article. Clinical Trial.
A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine.
Vesikari T, Karvonen A, Korhonen T, Edelman K, Vainionpää R, Salmi A, Saville MK, Cho I, Razmpour A, Rappaport R, O'Neill R, Georgiu A, Gruber W, Mendelman PM, Forrest B; CAIV-T Transmission Study Group. Vesikari T, et al. Among authors: korhonen t. Pediatr Infect Dis J. 2006 Jul;25(7):590-5. doi: 10.1097/01.inf.0000220229.51531.47. Pediatr Infect Dis J. 2006. PMID: 16804427 Clinical Trial.
Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study.
Pepin S, Szymanski H, Rochín Kobashi IA, Villagomez Martinez S, González Zamora JF, Brzostek J, Huang LM, Chiu CH, Chen PY, Ahonen A, Forstén A, Seppä I, Quiroz RF, Korhonen T, Rivas E, Monfredo C, Hutagalung Y, Menezes J, Vesikari T. Pepin S, et al. Among authors: korhonen t. Hum Vaccin Immunother. 2016 Dec;12(12):3072-3078. doi: 10.1080/21645515.2016.1212143. Epub 2016 Aug 26. Hum Vaccin Immunother. 2016. PMID: 27565435 Free PMC article. Clinical Trial.
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC; ZOE-70 Study Group. Cunningham AL, et al. Among authors: korhonen t. N Engl J Med. 2016 Sep 15;375(11):1019-32. doi: 10.1056/NEJMoa1603800. N Engl J Med. 2016. PMID: 27626517 Free article. Clinical Trial.
559 results